非小細胞肺癌的全球市場 - 市場規模，佔有率，成長分析:各治療法(標靶治療，免疫療法)，產業預測(2023年～2030年)

Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy) - Industry Forecast 2023-2030

出版日期: 2023年04月12日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球非小細胞肺癌的市場規模，2021年為236億6,489萬美金，在預測期間(2023年～2030年)預計以13.9％的年複合成長率成長，從2022年的269億4,836萬美元到2030年擴大到763億3,472萬美元。

肺癌，尤其是非小細胞肺癌，在全球成為癌症相關死亡的主要原因。非小細胞肺癌的盛行率和發病率增加，促進有效的診斷用具，治療的選項，對支持療法手段的需求。高齡化，抽煙，環境污染物質的暴露，生活方式要素等，推動非小細胞肺癌的負擔增加。

本報告提供全球非小細胞肺癌市場相關調查，市場概要，親市場分析，市場動態及預測，各市場區隔、地區的市場分析，企業簡介等資訊。

市場概要
市場規模
市場動態
- 促進因素
- 機會
- 阻礙因素
- 課題
主要的市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 知識產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 革新矩陣
- 開發中產品的分析
- 宏觀經濟指標
- 主要的投資分析
- 主要的成功因素
- 競爭的程度

市場動態及預測

市場動態
- 促進因素
- 機會
- 阻礙因素
- 課題
法規情形
波特分析
- 競爭企業間的敵對關係
- 替代品的威脅
- 買方議價能力
- 新加入業者的威脅
- 供給企業談判力
未來混亂相關Skyquest的特別考察
- 政治影響
- 經濟影響
- 社會影響
- 技術性影響
- 環境的影響
- 法律上的影響

全球非小細胞肺癌市場:各治療法

市場概要
標靶治療
免疫療法
化療

全球非小細胞肺癌的市場規模:各地區

市場概要
北美
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
南美
- 巴西
- 其他南美國家
中東、非洲
- GCC各國
- 南非
- 其他中東、非洲

競爭情形

前五名公司的比較
主要企業的市場定位(2021年)
主要的市場參與企業採用的策略
主要成功策略
- 各開發
- 各企業
- 各年度
市場上最近的活動
主要企業的市場佔有率(2021年)

主要企業簡介

Roche
AstraZeneca
Merck & Co.
Bristol-Myers Squibb
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Celgene Corporation
Boehringer Ingelheim
AbbVie Inc.
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Sanofi S.A.
GlaxoSmithKline
Johnson & Johnson
Amgen Inc.
Ipsen S.A.
Eisai Co., Ltd.
Taiho Oncology, Inc.
Gilead Sciences, Inc.

簡介目錄

Product Code: SQMIG25K2005

Global Non-Small Cell Lung Cancer Market size was valued at USD 23664.89 million in 2021 and is poised to grow from USD 26948.36 million in 2022 to USD 76334.72 million by 2030, growing at a CAGR of 13.9% in the forecast period (2023-2030).

The global non-small cell lung cancer (NSCLC) market refers to the pharmaceutical and biotechnology industry focused on the diagnosis, treatment, and management of non-small cell lung cancer, which is the most common type of lung cancer. NSCLC accounts for a significant portion of lung cancer cases globally and encompasses various subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The NSCLC market involves the development of targeted therapies, immunotherapies, chemotherapy, and supportive care options to improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.

Driver

Lung cancer, particularly NSCLC, remains a leading cause of cancer-related deaths worldwide. The increasing prevalence and incidence of NSCLC drive the demand for effective diagnostic tools, treatment options, and supportive care measures. Aging populations, tobacco smoking, exposure to environmental pollutants, and lifestyle factors contribute to the rising burden of NSCLC. Precision medicine approaches, such as molecular profiling and genomic testing, have revolutionized the treatment landscape for NSCLC. Targeted therapies that specifically target genetic mutations and alterations in cancer cells have shown promising results in improving patient outcomes. The development of companion diagnostics and personalized treatment strategies fuels the growth of the NSCLC market.

Restraint

NSCLC tumors can develop resistance to targeted therapies and immunotherapies over time. Tumor heterogeneity, the presence of different subclones within a tumor, contributes to treatment resistance and poses challenges in achieving durable responses. Overcoming drug resistance and understanding tumor heterogeneity are ongoing research priorities in the NSCLC market.

Market Trends

The NSCLC market is witnessing a shift towards combination therapies that involve the use of multiple treatment modalities, such as targeted therapies, immunotherapies, and chemotherapy. Combining therapies with different mechanisms of action aims to enhance treatment efficacy, overcome resistance, and improve patient outcomes. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in blood samples, are gaining importance in the diagnosis and monitoring of NSCLC. These non-invasive tests offer the potential for real-time monitoring of tumor mutations and treatment response. Companion diagnostics that identify predictive biomarkers for targeted therapies and immunotherapies continue to play a crucial role in treatment decision-making. The NSCLC market is increasingly focused on patient-centric care, emphasizing the holistic management of patients' physical, emotional